[Federal Register Volume 79, Number 83 (Wednesday, April 30, 2014)]
[Notices]
[Pages 24439-24440]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-09766]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-14-14VP]
Proposed Data Collections Submitted for Public Comment and
Recommendations
In compliance with the requirement of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for opportunity for public comment on
proposed data collection projects, the Centers for Disease Control and
Prevention (CDC) will publish periodic summaries of proposed projects.
To request more information on the proposed projects or to obtain a
copy of the data collection plans and instruments, call 404-639-7570
and send comments to Leroy Richardson, 1600 Clifton Road, MS-D74,
Atlanta, GA 30333 or send an email to [email protected].
Comments are invited on: (a) Whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information technology. Written comments should be received
within 60 days of this notice.
Proposed Project
Community Context Matters Study--New--National Center for HIV/AIDS,
Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease
Control and Prevention (CDC).
Background and Brief Description
The daily use of specific antiretroviral medications by persons
without human immunodeficiency virus (HIV) infection, but at high risk
of sexual or injection exposure to HIV has been shown to be a safe and
effective HIV prevention method. The Food and Drug Administration
approved the use of Truvada[supreg] for preexposure prophylaxis (PrEP)
in July 2012 and CDC has issued clinical practice guidelines for its
use. With approximately 50,000 new HIV infections each year, increasing
rates of infection for young MSM, and continuing severe disparities in
HIV infection among African-American men and women, incorporation of
PrEP into HIV prevention is important. However, as a new prevention
tool in very early stages of introduction and use, there is much we
need to learn about how to implement PrEP in a real world setting and
the need to develop and validate new measurement tools to capture this
information.
CDC is requesting Office of Management and Budget (OMB) approval to
collect data over a three-year period that will be used to (1) assess
the utility of new measures developed or adapted to collect information
related to this new intervention (PrEP) and (2) evaluate community
contextual factors that may impact the acceptability and successful
introduction of a new HIV prevention method. The project will be
conducted in communities in each of four cities where PrEP has recently
become available through a local community health center.
Once per year for three years, two surveys will be conducted: (1) A
community-based survey to be administered to 40 persons per city
approached in public venues in the catchment areas of the PrEP clinics,
and (2) a key stakeholder survey to be administered to 10 community HIV
leaders nominated by PrEP clinic staff and HIV community-based
organizations in the clinic communities.
[[Page 24440]]
Both surveys will collect data on the demographics of the participants,
knowledge of PrEP, misinformation about PrEP, and attitudes about it.
The neighborhood survey will also include questions about basic HIV
knowledge, attitudes, and beliefs as well as information about sexual
and drug use behaviors that are indications for PrEP use. For the
stakeholder survey, additional questions will be included about type of
organization where they work and organizational experience with PrEP.
Surveys will be administered face-to-face by trained, local
interviewers.
There are no costs to respondents other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of
Type of respondent Form name Number of responses per Average hours Total response
respondents respondent per response burden (hours)
----------------------------------------------------------------------------------------------------------------
Neighborhood Survey Street Neighborhood 720 1 5/60 60
Interview Participant. Interview
Recruitment
Script and
Informed
Consent.
Key Stakeholder Participant... Key Stakeholder 180 1 5/60 15
Telephone
Recruitment
Script and
Informed
consent.
Street Interview Participant.. Survey.......... 480 1 20/60 160
Key Stakeholder Participant... Survey.......... 120 1 20/60 40
---------------------------------------------------------------
Total..................... ................ .............. .............. .............. 275
----------------------------------------------------------------------------------------------------------------
LeRoy Richardson,
Chief, Information Collection Review Office, Office of Scientific
Integrity, Office of the Associate Director for Science, Office of the
Director, Centers for Disease Control and Prevention.
[FR Doc. 2014-09766 Filed 4-29-14; 8:45 am]
BILLING CODE 4163-18-P